Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
ResMed Stock Is S&P 500's Worst Performer. GLP-1 Drugs Are a Risk. -- Barrons.com
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Express News | Axcelead Drug Discovery Partners: Entered R&D Collaboration With Lilly for Drug Discovery Programs
Unhappy with the high stock price of weight-loss drugs, US senators are pressuring Novo-Nordisk: generic drug prices can be lower than $100/month.
Generic drug companies can sell generic versions of novo-nordisk a/s (NVO.US) diabetes drug Ozempic for less than $100 per month.
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Weight-loss Drug Competition Heats up With Growing Pill Market
Looking Into Eli Lilly's Recent Short Interest
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Unpacking the Latest Options Trading Trends in Eli Lilly
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Eli Lilly and Company (LLY): Among Morgan Stanley's Best Stock Picks for 2025
Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $885 Price Target
Eli Lilly Analyst Ratings